Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Pertile

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
International Journal of Health Care Finance and Economics|January 20, 2009
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomographyPaolo Pertile
Applied Health Economics and Health Policy|December 3, 2019
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and CompetitionRosella Levaggi, Paolo Pertile
Health Economics|June 16, 2020
Which valued-based price when patients are heterogeneous?Rosella Levaggi, Paolo Pertile
Health Economics|July 10, 2021
A reply to "Who would benefit from average value-based pricing?"Rosella Levaggi, Paolo Pertile
Journal of Public Health Research|August 30, 2014
Public health interventions: evaluating the economic evaluationsMartin Forster, Paolo Pertile
Applied Health Economics and Health Policy|February 5, 2020
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition"Rosella Levaggi, Paolo Pertile
Health Economics|December 11, 2012
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspectiveMartin Forster, Paolo Pertile
Journal of Health Economics|September 16, 2021
R&D and market size: Who benefits from orphan drug legislation?Simona Gamba, Laura Magazzini, Paolo Pertile
Health Economics|July 7, 2020
The impact of managed entry agreements on pharmaceutical pricesSimona Gamba, Paolo Pertile, Sabine Vogler
Health Policy (Amsterdam, Netherlands)|August 19, 2025
The 2023 European Commission proposal and the 2024 European Parliament proposal for the EU pharmaceutical legislation: policy content analysisSimona Gamba, Laura Magazzini, Paolo Pertile
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
International Journal of Health Care Finance and Economics|January 20, 2009
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomographyPaolo Pertile
Applied Health Economics and Health Policy|December 3, 2019
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and CompetitionRosella Levaggi, Paolo Pertile
Health Economics|June 16, 2020
Which valued-based price when patients are heterogeneous?Rosella Levaggi, Paolo Pertile
Health Economics|July 10, 2021
A reply to "Who would benefit from average value-based pricing?"Rosella Levaggi, Paolo Pertile
Journal of Public Health Research|August 30, 2014
Public health interventions: evaluating the economic evaluationsMartin Forster, Paolo Pertile
Applied Health Economics and Health Policy|February 5, 2020
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition"Rosella Levaggi, Paolo Pertile
Health Economics|December 11, 2012
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspectiveMartin Forster, Paolo Pertile
Journal of Health Economics|September 16, 2021
R&D and market size: Who benefits from orphan drug legislation?Simona Gamba, Laura Magazzini, Paolo Pertile
Health Economics|July 7, 2020
The impact of managed entry agreements on pharmaceutical pricesSimona Gamba, Paolo Pertile, Sabine Vogler
Health Policy (Amsterdam, Netherlands)|August 19, 2025
The 2023 European Commission proposal and the 2024 European Parliament proposal for the EU pharmaceutical legislation: policy content analysisSimona Gamba, Laura Magazzini, Paolo Pertile
Pageof 3